CATTANEO, DANIELE
CATTANEO, DANIELE
Dipartimento di Oncologia ed Emato-Oncologia
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
2024 T. Barbui, A. Carobbio, V. De Stefano, A. Alvarez-Larran, A. Ghirardi, G. Carioli, F. Fenili, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, L. Calabresi, G.G. Loscocco, P. Guglielmelli, F. Gesullo, S. Betti, F. Ramundo, F. Lunghi, L. Scaffidi, C. Bucelli, D. Cattaneo, N. Vianelli, M. Bellini, M.C. Finazzi, G. Tognoni, A. Rambaldi, A.M. Vannucchi
Prognostic and Predictive Models in Myelofibrosis
2024 B. Mora, C. Bucelli, D. Cattaneo, V. Bellani, F. Versino, K. Barbullushi, N. Fracchiolla, A. Iurlo, F. Passamonti
Neutrophilic and eosinophilic dermatoses associated with hematological malignancy
2024 C.A. Maronese, F. Derlino, C. Moltrasio, D. Cattaneo, A. Iurlo, A.V. Marzano
Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases
2024 D. Cattaneo, A. Marchetti, C. Bucelli, N. Galli, M. Lionetti, V. Bellani, U. Gianelli, F. Passamonti, N. Bolli, A. Iurlo
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
2024 F. Palandri, G. Auteri, E. Abruzzese, G. Caocci, M. Bonifacio, F. Mendicino, R. Latagliata, A. Iurlo, F. Branzanti, B. Garibaldi, M.M. Trawinska, D. Cattaneo, M. Krampera, O. Mulas, E.A. Martino, M. Cavo, N. Vianelli, S. Impera, F. Efficace, F. Heidel, M. Breccia, E.M. Elli, G.A. Palumbo
Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib
2024 D. Cattaneo, N. Galli, C. Bucelli, C.A. Fidanza, V. Bellani, S. Artuso, P. Bianchi, D. Consonni, F. Passamonti, A. Iurlo
Treatment‐free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects
2024 D. Cattaneo, C. Bucelli, V. Bellani, B. Mora, A. Iurlo
Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis
2024 V. Abbonante, A.I. Karkempetzaki, C. Leon, A. Krishnan, N. Huang, C.A. Di Buduo, D. Cattaneo, C.M. Ward, S. Matsuura, I. Guinard, J. Weber, A. De Acutis, G. Vozzi, A. Iurlo, K. Ravid, A. Balduini
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial
2024 B. Rocca, A. Tosetto, G. Petrucci, E. Rossi, S. Betti, D. Soldati, A. Iurlo, D. Cattaneo, C. Bucelli, A. Dragani, M. Di Ianni, P. Ranalli, F. Palandri, N. Vianelli, E. Beggiato, G. Lanzarone, M. Ruggeri, G. Carli, E.M. Elli, R. Renso, M.L. Randi, I. Bertozzi, G.G. Loscocco, A. Ricco, G. Specchia, A.M. Vannucchi, F. Rodeghiero, V. De Stefano, C. Patrono
Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis
2024 D. Capitanio, F.R. Calledda, V. Abbonante, D. Cattaneo, M. Moriggi, B. Niccolò, C. Bucelli, D. Tosi, U. Gianelli, A.M. Vannucchi, A. Iurlo, C. Gelfi, A. Balduini, A. Malara
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
2024 F. Palandri, G.A. Palumbo, G. Benevolo, A. Iurlo, E.M. Elli, E. Abruzzese, N. Polverelli, M. Tiribelli, G. Auteri, A. Tieghi, G. Caocci, G. Binotto, F. Cavazzini, F. Branzanti, E. Beggiato, M. Miglino, C. Bosi, M. Crugnola, M. Bocchia, B. Martino, N. Pugliese, L. Scaffidi, M. Venturi, A. Duminuco, A. Isidori, D. Cattaneo, M. Krampera, F. Pane, D. Cilloni, G. Semenzato, R.M. Lemoli, A. Cuneo, M.M. Trawinska, N. Vianelli, M. Cavo, M. Bonifacio, M. Breccia
The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective
2024 C. Pescia, G. Lopez, D. Cattaneo, C. Bucelli, U. Gianelli, A. Iurlo
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib
2024 O. Mulas, E. Abruzzese, L. Luciano, A. Iurlo, I. Attolico, F. Castagnetti, S. Galimberti, M. Bonifacio, M. Annunziata, A. Gozzini, E.M. Orlandi, F. Stagno, G. Binotto, P. Pregno, C. Fozza, M. Loi, M.M. Trawinska, F. De Gregorio, D. Cattaneo, F. Albano, M. Iezza, C. Baratè, L. Scaffidi, C. Elena, V. Giai, E. Scalzulli, M. Breccia, G. La Nasa, G. Caocci
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
2023 A. Iurlo, D. Cattaneo, D. Consonni, F. Castagnetti, M.C. Miggiano, G. Binotto, M. Bonifacio, G. Rege-Cambrin, M. Tiribelli, F. Lunghi, A. Gozzini, P. Pregno, E. Abruzzese, I. Capodanno, C. Bucelli, M. Pizzuti, S. Artuso, M. Iezza, E. Scalzulli, G. La Barba, A. Maggi, S. Russo, C. Elena, A.R. Scortechini, A. Tafuri, R. Latagliata, G. Caocci, M. Bocchia, S. Galimberti, L. Luciano, C. Fava, R. Foà, G. Saglio, G. Rosti, M. Breccia
Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib
2023 A. Iurlo, N. Galli, C. Bucelli, S. Artuso, D. Consonni, D. Cattaneo
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
2023 F. Palandri, G. Alberto Maria PALUMBO, M. Bonifacio, E. Maria Elli, M. Tiribelli, G. Auteri, M.M. Trawinska, N. Polverelli, G. Benevolo, A. Tieghi, F. Cavalca, G. Caocci, E. Beggiato, G. Binotto, F. Cavazzini, M. Miglino, C. Bosi, M. Crugnola, M. Bocchia, B. Martino, N. Pugliese, M. Venturi, A. Isidori, D. Cattaneo, M. Krampera, F. Pane, D. Cilloni, G. Semenzato, R.M. Lemoli, A. Cuneo, E. Abruzzese, F. Branzanti, N. Vianelli, M. Cavo, F. Heidel, A. Iurlo, M. Breccia
Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort
2023 D. Cattaneo, C. Bucelli, A. Marchetti, M. Lionetti, E. Fermo, V. Bellani, C. De Magistris, A. Maeda, A. Marella, M. Primignani, D. Consonni, U. Gianelli, A. Neri, L. Baldini, N. Bolli, A. Iurlo
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
2023 F. Palandri, M. Breccia, C. Mazzoni, G. Auteri, E.M. Elli, M.M. Trawinska, N. Polverelli, M. Tiribelli, G. Benevolo, A. Iurlo, A. Tieghi, F.H. Heidel, G. Caocci, E. Beggiato, G. Binotto, F. Cavazzini, M. Miglino, C. Bosi, M. Crugnola, M. Bocchia, B. Martino, N. Pugliese, M. Biondo, M. Venturi, L. Scaffidi, A. Isidori, D. Cattaneo, M. Krampera, F. Pane, D. Cilloni, G. Semenzato, R.M. Lemoli, A. Cuneo, E. Abruzzese, D. Bartoletti, S. Paglia, N. Vianelli, M. Cavo, M. Bonifacio, G.A. Palumbo
Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs
2023 A. Iurlo, C. Bucelli, D. Cattaneo
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
2023 F. Palandri, E.M. Elli, G. Auteri, M. Bonifacio, G. Benevolo, F.H. Heidel, S. Paglia, M.M. Trawinska, C. Bosi, E. Rossi, M. Tiribelli, A. Tieghi, A. Iurlo, N. Polverelli, G. Caocci, G. Binotto, F. Cavazzini, E. Beggiato, D. Cilloni, C. Tatarelli, F. Mendicino, M. Miglino, M. Bocchia, M. Crugnola, C. Mazzoni, A.D. Romagnoli, G. Rindone, S. Ceglie, A. D'Addio, E. Santoni, D. Cattaneo, D. Bartoletti, R.M. Lemoli, M. Krampera, A. Cuneo, G.C. Semenzato, R. Latagliata, E. Abruzzese, N. Vianelli, M. Cavo, A. Andriani, V. De Stefano, G.A. Palumbo, M. Breccia